AVTX (Avalo Therapeutics) Float Percentage Of Total Shares Outstanding: 99.83% (As of Jun. 28, 2026)


AVTX Avalo Therapeutics Inc AVTX
23 GF Score
Price $18.16
GF Value $0.03
Valuation Significantly Overvalued
! 5 Warning Signs
View Full Analysis

What is Avalo Therapeutics Float Percentage Of Total Shares Outstanding?

Avalo Therapeutics AVTX +1.11% 23 Float Percentage Of Total Shares Outstanding is 99.83% as of Jun. 28, 2026. GuruFocus rates AVTX with a GF Score™ of 23/100 and a GF Value™ of $0.03 (Significantly Overvalued). The stock has 5 warning signs investors should review.

Float percentage of total shares outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Avalo Therapeutics's float shares is 52.48 Mil. Avalo Therapeutics's total shares outstanding is 52.57 Mil. Avalo Therapeutics's float percentage of total shares outstanding is 99.83%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Avalo Therapeutics's Insider Ownership is 10.23%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Avalo Therapeutics's Institutional Ownership is 87.71%.

AVTX
23GF Score
Avalo Therapeutics Inc AVTX
Float Percentage Of Total Shares Outstanding is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Avalo Therapeutics Float Percentage Of Total Shares Outstanding Calculation

It is the percentage of float shares out of the total shares outstanding.

Avalo Therapeutics's Float Percentage of Total Shares Outstanding for today is calculated as follows:

Float Percentage of Total Shares Outstanding=Float Shares/Total Shares Outstanding
=52.48/52.57
=99.83%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Float Percentage Of Total Shares Outstanding of 99.83% mean?
Avalo Therapeutics (AVTX) has a Float Percentage Of Total Shares Outstanding of 99.83% as of Jun. 28, 2026. Float percent of shares outstanding equals the percent of float shares relative to total shares. View historical data on Avalo Therapeutics and its competitors.
Is Avalo Therapeutics' Float Percentage Of Total Shares Outstanding too high?
Avalo Therapeutics' current Float Percentage Of Total Shares Outstanding is 99.83%. Overall, Avalo Therapeutics has a GF Score™ of 23/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Avalo Therapeutics' Float Percentage Of Total Shares Outstanding compare to EVMN and TBPH?
Avalo Therapeutics' Float Percentage Of Total Shares Outstanding of 99.83% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Float Percentage Of Total Shares Outstanding for a Biotechnology company?
A good Float Percentage Of Total Shares Outstanding depends on the Biotechnology industry context. However, Float Percentage Of Total Shares Outstanding should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Float Percentage Of Total Shares Outstanding mean?
A high Float Percentage Of Total Shares Outstanding can signal that a stock is expensive relative to its fundamentals. Float percent of shares outstanding equals the percent of float shares relative to total shares. View historical data on Avalo Therapeutics and its competitors. Avalo Therapeutics's current Float Percentage Of Total Shares Outstanding is 99.83%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Avalo Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Avalo Therapeutics (AVTX) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.03, compared to a current price of $18.16 — trading 60433.3% above its estimated fair value. The current Float Percentage Of Total Shares Outstanding is 99.83%. Avalo Therapeutics' overall GF Score™ is 23/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Float Percentage Of Total Shares Outstanding calculated?
Float Percentage Of Total Shares Outstanding is calculated from a company's financial statements. For Avalo Therapeutics (AVTX), the current Float Percentage Of Total Shares Outstanding is 99.83% as of Jun. 28, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Avalo Therapeutics (AVTX) Overvalued in 2026?

Based on GuruFocus' analysis, Avalo Therapeutics stock appears to be overvalued. The current stock price of $18.16 is trading 60433.3% above its estimated GF Value™ of $0.03. GuruFocus considers Avalo Therapeutics to be Significantly Overvalued.

Key valuation signals for AVTX:

  • Float Percentage Of Total Shares Outstanding: 99.83%
  • GF Value™: $0.03 vs. price of $18.16 (60433.3% above fair value)
  • GF Score™: 23/100 with 5 warning signs

No single metric tells the full story. See the AVTX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Avalo Therapeutics Business Description

Other Exchanges C6K0:Germany
Address 1500 Liberty Ridge Drive, Suite 321, Wayne, PA, USA, 19087
Avalo Therapeutics Inc is a clinical stage biotechnology company fully dedicated to developing IL-1B-based treatments for immune-mediated inflammatory diseases. The company's asset is Abdakibart (AVTX-009) an anti-IL-1B monoclonal antibody ("mAb"), targeting inflammatory diseases. Avalos pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein), AVTX-006 and AVTX-913.
23GF Score

Get the complete analysis for AVTX

Float Percentage Of Total Shares Outstanding is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$18.16
Price
$0.03
GF Value